Coherus BioSciences Inc and Shanghai Junshi Biosciences Co Ltd Virtual Investor Event to Discuss Toripalimab Clinical Data from the ASCO Annual Meeting Transcript
Thank you for standing by, and welcome to the Coherus and Junshi BioSciences post-ASCO investor event. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions) I would now like to hand the conference over to your host, Chief Financial Officer, McDavid Stilwell. Please go ahead.
Thank you. Good afternoon, everyone. And on behalf of Coherus and our immuno-oncology partner, Junshi Biosciences, I want to welcome you to our conference call review toripalimab clinical data presented at ASCO and key elements of the ongoing toripalimab clinical development program.
During the course of this conference call, we will -- we will refer to the slide deck that is posted now on the Events and Presentations page of the Investor Relations section of the Coherus website.
Today's call includes forward-looking statements regarding Coherus' current expectations. These statements include, but are not limited to, our ability to advance toripalimab and other product
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)